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Abstract
The field of molecular imaging has recently seen rapid advances in the development of novel contrast agents
and the implementation of insightful approaches to monitor biological processes non-invasively. In particular,
superparamagnetic iron oxide nanoparticles (SPIO) have demonstrated their utility as an important tool for
enhancing magnetic resonance contrast, allowing researchers to monitor not only anatomical changes, but
physiological and molecular changes as well. Applications have ranged from detecting inflammatory diseases
via the accumulation of non-targeted SPIO in infiltrating macrophages to the specific identification of cell
surface markers expressed on tumors. In this article, we attempt to illustrate the broad utility of SPIO in
molecular imaging, including some of the recent developments, such as the transformation of SPIO into an
activatable probe termed the magnetic relaxation switch.
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Abstract—The field of molecular imaging has recently seen rapid
advances in the development of novel contrast agents and the
implementation of insightful approaches to monitor biological
processes non-invasively. In particular, superparamagnetic iron
oxide nanoparticles (SPIO) have demonstrated their utility as an
important tool for enhancing magnetic resonance contrast, al-
lowing researchers to monitor not only anatomical changes, but
physiological and molecular changes as well. Applications have
ranged from detecting inflammatory diseases via the accumulation
of non-targeted SPIO in infiltrating macrophages to the specific
identification of cell surface markers expressed on tumors. In this
article, we attempt to illustrate the broad utility of SPIO in molec-
ular imaging, including some of the recent developments, such as
the transformation of SPIO into an activatable probe termed the
magnetic relaxation switch.
Keywords—Molecular imaging, Nanoparticles, SPIO, Magnetic
resonance.
INTRODUCTION
The field of molecular imaging has recently gained
widespread interest across a spectrum of disciplines. While
it lacks a universal definition, molecular imaging can be
outlined as the “non-invasive, quantitative, and repetitive
imaging of targeted macromolecules and biological pro-
cesses in living organisms.”57 The underlying premise of
molecular imaging is that most disease processes can be
identified by altered molecular profiles and/or cell behav-
ior prior to visual anatomic alterations. Such insight could
potentially allow for (1) the early detection of disease, (2)
more accurate prognoses and personalized treatments, (3)
the ability to monitor the effectiveness of therapeutic treat-
ments, and (4) improvements in our understanding of how
cells behave and interact in their intact environment in living
subjects. Therefore, it is envisioned that molecular imag-
ing could have a profound effect on progress in both the
laboratory and the clinic.
Address correspondence to Andrew Tsourkas, Cellular and Molec-
ular Imaging Group, Department of Bioengineering, University of
Pennsylvania, 3320 Smith Walk, Philadelphia, PA 19104. Electronic mail:
atsourk@seas.upenn.edu
In response to the promise of molecular imaging, the
amalgamated field of bioengineering and nanotechnology
has emerged to provide researchers and clinicians with a
multiplying array of possibilities. The technology of mag-
netic nanoparticle probes, in particular, has seen increased
efforts devoted to maturing its potential as a central tool for
efficient, cross-application, molecular imaging. Although
particles of iron oxide have been used as magnetic con-
trast agents for over 45 years,46 refinement in the synthesis
and coating of magnetic nanoparticles, especially in the
last decade, has led to their employment in an abundance
of novel biological applications. These applications in-
clude blood pooling, tissue and cell specific contrast agents
for magnetic resonance (MR) imaging, cell tracking, and
biomolecular detection.
Typically, magnetic nanoparticle probes for biomedical
applications are comprised of nanoscale superparamagnetic
iron oxide (SPIO) cores of magnetite and/or maghemite
encased in polysaccharide, synthetic polymer, or monomer
coatings. While other embodiments for MR contrast agents
exist, including different transition metal systems such as
cobalt-ferrite97 or soluble paramagnetic chelates, such as
gadolinium,40,84 they are outside the scope of this review
and will not be discussed in depth. Rather, this review will
focus specifically on the use of SPIO as a molecular imag-
ing agent. In particular, we will first discuss some of the
physico-chemical properties and synthesis strategies of iron
oxide nanoparticles. Then, we will provide an overview of
the many exciting applications of SPIO both as a passive
and active targeting imaging agent. Finally, we will exam-
ine several emerging applications for SPIO including cell
tracking and magnetic relaxation switches.
PHYSICO-CHEMICAL PROPERTIES OF SPIO
Iron Oxide Core Structure
SPIO typically consist of two components, an iron oxide
core and a hydrophilic coating. The SPIO core can be com-
posed of magnetite (Fe3O4) and/or maghemite (γ Fe2O3).
Maghemite is the ferrimagnetic cubic form of Fe(III) oxide
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and it differs from the inverse spinel structure of magnetite
through vacancies on the cation sublattice. However, both
compositions possess similar lattice parameters at 8.396
and 8.346 ˚A for magnetite and maghemite, respectively.14
Oxidation of synthesized SPIO converts Fe3O4 to γ Fe2O3
and can be accomplished through exposure to oxygen or
oxidizing agents. This results in the change of the material
appearance from a black-brown to a red-brown as Fe2+ in
the magnetite lattice oxidizes. It should be noted, however,
that the two iron oxide structures possess similar magnetic
properties, although maghemite does have a slightly lower
saturation magnetization.25,141
Classifications
SPIO sizes range greatly from 2 to 3 nm for citrate
inhibited growth SPIO,89 tens of nanometers for polymer-
coated polycrystalline iron oxide nanoparticles through to
micrometers for orally ingestible contrast agents. Larger
diameters are available and are useful in such enterprises
as cell tracking134,58 and separation,73 cell rheology and
membrane deformation,38,151 and as contrast agents for the
gastrointestinal tract,54 but have limited functionality in
molecular imaging applications due to their limited accessi-
bility to the neo- and microvasculature. Categories of SPIO,
based on their overall diameter (including iron oxide core
and hydrated coating), are noted in the literature152 as oral-
SPIO at between 300 nm and 3.5 µm; standard SPIO (SS-
PIO) at approximately 60–150 nm; ultrasmall SPIO (US-
PIO) of approximately 10–40 nm156; and monocrystalline
iron oxide nanoparticles (MION—a subset of USPIO34) of
approximately 10–30 nm.135,158 MION nanoparticles are so
named to underline the single crystal nature of their core.
This is in contrast to SPIO greater than 50 nm that are com-
prised of multiple iron oxide crystals. Agents of all types
excluding the MION category SPIO have either completed
or are currently undergoing clinical testing (see Table 1).
Generally speaking, all SPIO agents with less than a 50 nm
diameter have been used for similar molecular imaging ap-
plications in vivo. Therefore, to avoid confusion, the term
SPIO will be used to refer to all USPIO, MION, and CLIO
(a form of MION with cross-linked dextran coating) for the
remainder of this article.
Magnetism
The magnetic properties present in some ferromagnetic
materials are the result of aligned unpaired electron spins.
For these materials, magnetization is evident even in the
absence of an external field. In a non-magnetized ferro-
magnetic material, magnetic domains (so called Weiss-
domains) at short range are aligned, but at long range
adjacent domains are anti-aligned. The transition between
these two domains is called a Bloch wall. At the nanometer
scale (∼14 nm), the formation of Bloch walls becomes
thermodynamically unfavorable leading to the formation
of single domain crystals, which are classified as super-
paramagnetic.35,137 The term superparamagnetic refers to
the characteristic strong paramagnetic nature of the parti-
cles at this scale. Paramagnetic materials are distinguished
through the tendency of their atomic magnetic dipoles to
align with an external magnetic field, their small positive
magnetic susceptibility (i.e., ability to strengthen the field
they are in), and their random orientation in the absence
of a magnetic field (due to Brownian fluctuations). SPIO
have much larger susceptibilities (compared with strictly
paramagnetic materials) as the entire crystal aligns with the
applied field due to its single crystal nature.
When SPIO are placed in an external magnetic field
their moments align in the direction of the magnetic field
and enhance the magnetic flux. This ability to elicit sub-
stantial disturbances in the local magnetic field through
large magnetic moments leads to a rapid dephasing of sur-
rounding protons, generating a detectable change in the
MR signal. Thus, the imaging capability provided is not
from the SPIO intrinsically, but through their influence on
longitudinal and transverse relaxation of the surrounding
nuclei. Although the ability of SPIO to significantly reduce
the spin–spin relaxation (T2) time is generally relied on for
generating MR contrast,68,99 it has also been demonstrated
that SPIO can generate sufficient T1 contrast for biomed-
ical applications as well; SPIO possess both high R1 and
R2 relaxivities.118,127 Upon removal of the magnetic field,
Brownian motion is sufficient to randomize the SPIO ori-
entations leaving no magnetic remanence. Brownian forces
also prevent the aggregation of the SPIO due to magnetic
attraction in solution.123
SPIO SYNTHESIS
There are several methods that are generally used to
produce magnetic iron oxide nanoparticles, described in a
rich patent and journal literature. Historically, long-term
grinding of bulk magnetite in the presence of stabilizing
surfactant produced the first documented ferrofluid.103 Such
mechanogrinding regimes are inherently time consuming
and expensive. Currently, perhaps the most commonly ac-
cepted approaches for creating SPIO for biomedical appli-
cations concentrate around coprecipitation and microemul-
sion methods, although numerous other approaches are
becoming more prevalent as the synthesis of SPIO with
uniform core diameters becomes more desirable.
Coprecipitation
The most common method for production of mag-
netic nanoparticle populations involves synthesis via the
coprecipitation of ferrous and ferric salts in an alkaline
medium.87,88,92,93,121 This synthesis approach can be con-
ducted either in the absence or presence of surface complex-
ing agents, such as dextran, polyethylene glycol (PEG), or
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Table 1. Examples and properties of commercial SPIO agents (updated from Wang,152).
Agent Class Trade and common names Status
Mean particle
size
AMI-121 Oral SPIO Lumirem, Gastromark, Ferumoxsil Approved >300 nm
OMP Oral SPIO Abdoscan Approved 3.5 µm
AMI-25 SSPIO Feridex, Endorem, Ferumoxide Approved 80–150 nm
SHU555A SSPIO Resovist Phase III 62 nm
AMI-227 USPIO Sinerem, Combidex, Ferumoxtran Phase III 20–40 nm
NC100150 USPIO Clariscan Completed phase II
(discontinued)
20 nm
CODE 7228 USPIO (Advanced magnetics) Phase II 18–20 nm
polyvinyl alcohol (PVA). Surface complexing agents are
often used to provide colloid stability and biocompatibil-
ity. Several SPIO-surface complexation agents are listed in
Table 2.
Bare SPIO (i.e., without surface complexing agents) are
created following the addition of a concentrated base to
a di- and trivalent ferrous salt solution.13 The precipitate
is isolated through magnetic decantation or centrifugation.
The precipitate is then treated with nitric or perchloric acid,
centrifuged and peptized (i.e., colloidally dispersed) in wa-
ter. This produces an acidic magnetic sol. Likewise, alkaline
magnetic sols can be made using tetramethylammonium in
place of the perchloric or nitric acid.87 These magnetite
nanoparticles are polydisperse with a mean diameter of
approximately 10 nm and are roughly spherical in shape.13
Bare SPIO can subsequently be coated in monomers
and polymers (Table 2) through non-specific adsorption
following their purification to make them more suited for
biomedical applications.109 Alternatively, the monomers
and polymers may be grafted to the nanoparticles during
the precipitation step, although this will change the physical
characteristics of the resulting nanoparticles.13,32
One commonly used coating for bare SPIO is silica.
An advantage of coating contrast agents with silica is that
one is able to tap the established database for silica sur-
face modification.114 The degree of silica-coating can be
controlled,11 resulting in coverage thickness between 2 and
100 nm.85 The hydroxyl surface groups can be modified
to display functional amines and carboxyls, relevant for
further bioconjugation56 and the silica itself can be dye-
doped.85,114
As mentioned earlier, SPIO can also be formed directly
in the presence of a coating polymer, usually dextran,93,156
although a variety of coating systems are available
(Table 2).92,102 As with the bare SPIO, alkaline agents
are used to coprecipitate the di- and trivalent ferrous salts,
but here these salts have been dissolved directly in the
presence of dextran.92 The mean hydrodynamic radii of
the polydisperse polymer-coated SPIO typically vary from
∼20 to above 100 nm (this can be controlled by adjust-
ing synthesis parameters such as the dextran-to-iron ra-
tio), while the iron oxide core size typically ranges from
∼2 to 15 nm.135 Improved stability, including at ele-
vated temperatures, can be imparted to the nanoparticles
through an assortment of chemical modifications. The use
of carboxymethyl reduced dextran50 or cross-linking of
surface adsorbed filaments with agents such as epichloro-
hydrin,60,102 are just two examples of many. An impor-
tant enhancement of polymer-coated SPIO for molecular
imaging is their increased circulation lifetime95 in vivo as
the coating avoids the quick opsonization suffered by bare
nanoparticles.100
Table 2. Common surface coatings and complexation agents.
Coating material Advantages References
Citric, gluconic, oleic Larger SPIO core with thin organophillic coating 39, 48, 150
Dextran Long plasma half-life, modifications 4, 92, 102, 153
Polycarboxymethyl dextran Long plasma half-life, reduced diameter 50
Polyvinyl alcohol Longer plasma half-life 92, 109
Starches Wide pH stability, biocompatibility, availability,
modifications
74
PMMA Magnetic drug delivery vehicle 161
PLGA FDA approved biocompatible coating 79
PAM Multiple particle enmeshing matrix 91
PEG Long plasma half-life, chemical modifications 53, 126, 162
PEG-lipid Thin coating, available bioconjugation 101
Silane Reactive to alcohol and silane coupling agents 18, 136
Silica Inert, biocompatible coating 32
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A wide variety of factors can be adjusted in the synthe-
sis of the iron oxide nanoparticles in order to control size,
magnetic characteristics, stability in solution, surface prop-
erties, and coatings leaving the synthesis of nanoparticles
as more of an art than a science. The ionic strength and pH
of the coprecipitation solution can be adjusted to control
nanoparticle size over an order of magnitude (2–15 nm).66
In addition, adjustment of the Fe(III)–Fe(II) ratios, heat-
ing regimes, and the dextran–iron ratios can be used to
further control SPIO core size and overall hydrodynamic
radius.102,153 Although coprecipitation methods are widely
utilized due to their simplicity and ability to be scaled up
for large-scale reactions, the nanoparticles produced are
fairly polydisperse. As a result, numerous other methods
are currently being developed to make nanoparticles with
more uniform dimensions.
Microemulsion
Microemulsions (oil-in-water and water-in-oil) have re-
cently been adopted as nano-reactors for the synthesis of
SPIO due to the ability to control the size and shape of the
nanoparticles.111 In general, nanoparticles are synthesized
in oil-in-water microemulsions by suspending a ferrous
salt-surfactant precipitate to an aqueous solution. A base
(e.g., methylamine) is then added to form a magnetic pre-
cipitate. The size of nonstoichiometric mixed cobalt–zinc
ferrite nanoparticles was found to depend on the presence of
cobalt in the lattice.59 In another embodiment, surfactant-
(oleic acid) coated nanoparticles were added to a solution
composed of a melted lipophilic suspension and an aque-
ous phase. This warm transparent phase when dispersed
in cold water accomplished lipid coating of the colloidal
magnetite.63
The water-in-oil approach is a more common mi-
croemulsion synthesis technique for nanoparticles with
biomedical applicability. Strategies typically involve en-
closing “nanodroplets” of aqueous iron salts in a surfac-
tant coat that separates them from the surrounding or-
ganic solution (e.g., AOT in isooctane); to form reverse
micelles.29,113,132 To this, alkaline nanodroplets are added.
The SPIO are precipitated and oxidized within the nano-
sized micelle. Using variable reaction temperatures results
in SPIO with diameters of 3–12 nm. Metal concentration
and base concentration can also be used to vary nanoparticle
size.112
Microemulsions are an efficient way to manufacture
nanoparticles since the size of the microcavities formed can
be tightly controlled between ∼2 and 12 nm.111 Thus, this
approach results in fairly uniform populations of SPIO. Al-
though some microemulsion approaches produce nanopar-
ticles that are only soluble in organic solvents,78 these SPIO
can be given water-soluble coatings that prevent agglomera-
tion.101 It should be noted that while it is generally accepted
that microemulsion can produce SPIO with homogeneous
sizes, this is dependent on the approach and precision. Fur-
ther, microemulsion techniques have been criticized as an
approach for synthesizing larger nanoparticles due to the
formation of SPIO with poor crystallinity.10
Additional Methods
Numerous additional methods also exist for the con-
trolled synthesis of SPIO including ultrasound irradiation
and spray and laser pyrolysis. During ultrasound irradia-
tion (also referred to as sonochemical synthesis), the rapid
collapse of sonically generated cavities provides nanosec-
ond lifetime hot spots of ∼5000 K where ferrous salts are
instantly driven to form SPIO nanoparticles. Stabilization
through oleic acid allows for the production of a monodis-
persed nanocolloid of ∼8 nm.139 Using aerosol manufac-
turing techniques, such as spray and laser pyrolysis, contin-
uous high-production rate formation of nanoparticles can
be accomplished. In spray pyrolysis, a solution is sprayed
into a series of reactors where the solute condenses as the
solvent evaporates. Here, ferric ions are reduced to a mix-
ture of ferric and ferrous ions in an organic compound,
leading to SPIO formation.20 A microporous solid is then
sintered to a particle at high temperature. Laser pyrolysis
can be used to reduce the reaction volume, as a laser heats
a gaseous mixture of iron pentacarbonyl and air, produc-
ing nuclei that lead to small nanoparticles.147 Uniform and
well-crystallized nanoparticles are synthesized in a single
step.98 The high production rates of these methods come
at the cost exhaustive control over experimental conditions
and expensive equipment.
Recently, a method has been developed to synthesize
high-quality SPIO by thermal decomposition of different
iron precursors. Alivisatos’ group have used FeCup3 in
octylamine and trioctylamine at 250–300◦C to form a
monodisperse precipitate of maghemite.122 Work is ongo-
ing towards increasing the utility of thermally decomposed
nanoparticles for biomedical applications81; specifically,
to overcome their required suspension in organic solvents.
Finally, another synthesis route is layer-by-layer (LBL)
self-assembly, based on repeated submersion of a substrate
or colloidal template in solutions of oppositely charged
polyelectrolytes.28 Stepwise adsorption of ions allows
cores of nanoparticles or shells around existing particles to
form. Although the large size of the particles may remain a
limitation, Caruso et al. have developed protocols for dense
and hollow SPIO sub-micron particles with interesting
properties.21,22
BIOCOMPATIBILITY
The diameter and surface characteristics of the SPIO
contrast agents are of importance in terms of clearance,
cell response, and toxicity. In general, the spleen and liver
as a result of mechanical filtration sequester SPIO above
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approximately 200 nm in diameter. Particles below 10 nm
are removed rapidly through extravasation and renal clear-
ance.53 In order to prolong plasma half-life, amphiphilic
coatings are preferred, extending the circulation time of the
particulates from minutes to hours,104 thereby increasing
the targeting capabilities of the contrast agent.
To date, studies have shown that the polymer-coated
nanoparticles have minimal impact on cell viability and
function. After incubation with immortalized fibroblasts,
PEG-coated SPIO nanoparticles did not affect cell adhesion
behavior or morphology.52 Similarly, dextran-coated SPIO
labeled with the Tat-internalizing peptide showed no
significant effects on cell viability, clonogenic efficiency,
immunophenotypic changes, or biodistribution for human
hematopoietic cells.80 Nonetheless, studies have shown
that SPIO surface properties can influence the uptake
of nanoparticles by phagocytic cells. For example,
carboxydextran-coated SPIO (of equal or even smaller
sizes) appear to be internalized by macrophages to a
greater extent than dextran-coated SPIO.90 It should be
noted, however, that uptake of SPIO by macrophages is not
associated with cell activation as no interleukine-1 release
is observed.116
When used as a contrast agent in living subjects, adverse
events from USPIO (dextran-coated SPIO) were noted as
not serious, mild in severity, and short in duration.3 The
most common reactions were headache, back pain, vasodi-
latation, and hives. Magnetite biocompatibility has already
been proven.131,159 Following internalization, SPIO gener-
ally accumulate in lysosomes where the iron oxide core is
broken down to iron ions through low pH exposure and
these ions are incorporated into the hemoglobin pool.154
Intracellular dextranase further assist with the degrada-
tion process by cleaving the dextran moiety. The use of
dextran–iron complexes in vivo, stretches back over half
a century, initially as a means to treat anemia.41,83 Orig-
inally, dextran-coated iron oxide was developed to sub-
stitute for the ferritin iron complex, as a means to in-
travenously administer iron. The low toxicity of these
agents over soluble iron salts translates into higher in-
jectable concentrations of iron by as much as two orders of
magnitude.51
PASSIVE TARGETING
SPIO probes lacking explicit molecular specificity are
well known in the literature for imaging of biological sys-
tems via naturally directed physiological process. These
include non-targeted cellular uptake, enhanced retention in
tumors, macrophage phagocytosis, as well as accumulation
in the liver, spleen, and lymph nodes. T2-weighted im-
ages reveal the presence of the SPIO through the T2 relax-
ation shortening effect resulting from the accumulation of
nanoparticles. Propinquity of SPIO agents is a critical factor
in enhancing the T2 relaxation effect,140 as accumulation
of nanoparticles leads to more efficient transverse spin de-
phasing of water protons.17,47 Perhaps most important for
passive targeting is the hydrodynamic radius and the sur-
face charge of the SPIO (factors related to the SPIO coating
material), as these parameters control the circulation time
of the nanoparticles, accessibility to tissues, opsonization,
and rate of cell-type uptake.
Liver and Splenic Imaging
It has been demonstrated that larger nanoparticles
(∼150 nm hydrodynamic radius) such as the dextran-
coated SSPIO AMI-25 are non-specifically taken up by
Kupffer cells in the healthy liver, allowing for hepatic
imaging. Further, the absence of Kupffer cells in malig-
nancies has been exploited to allow for enhanced accuracy
in discerning between healthy and diseased tissue through
SPIO endowed contrast.117,133,149 In addition to the detec-
tion and characterization of liver lesions, larger nanopar-
ticles such as SHU555A and AMI-25 have also been
shown capable of detecting focal splenic tumors.5,157,160
Reimer et al., in imaging hepatic lesions, clearly show the
power of enhanced detection through the use of SPIO,117
(Fig. 1).
Lymph Node Imaging
In contrast to SSPIO, smaller iron oxide nanoparticles
(∼30 nm hydrodynamic radius) are found to accumulate in
lymph nodes.82,86,95,155 Specifically, the SPIO extravasate
from the vasculature to the interstitial space where they are
transported to the lymph nodes via the lymphatic vessels.
The absence of SPIO in lymph nodes as determined by
MR imaging has been shown to correlate with disturbances
in lymph node flow or architecture due to the presence of
metastases. The T2 shortening due to SPIO accumulation
was pronounced in normal nodes, allowing for significant
increases in positive predictive values and accuracy of di-
agnosis of node metastases3 (Fig. 2). Thus, while lacking
molecular targeting specificity, these agents have been used
to discern between metastatic and inflammatory tumors
through MR imaging.4,55
Cancer Imaging
Numerous studies have shown that in addition to detect-
ing lymph node metastases SPIO can also be used to detect
solid tumors directly. It has been found that SPIO passively
accumulate at the tumor site due to the presence of leaky
vasculature as well as from macrophage uptake.95,116,165
The extent of tumor extravasation depends on the porosity
of the angiogenic tumor vessels.
Enhanced detection of bone marrow is possible through
SPIO27,61 and possibly SSPIO, such as AMI-25 as well.146
Bone marrow lesions are usually detected with high sen-
sitivity, except in the complicating cases of children and
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FIGURE 1. Detection of cancer in the liver revealed through SPIO. (C) T2-weighted image without contrast agent indicates the
difficulty of determination of lesion. (D) SHU555A enhanced detection in the liver enhanced the conspicuity, leading all readers to
rate the signal increase as a definite lesion. Panels (C) and (D) from Fig. 3, in Reimers, 1990.117
adults with red marrow hyperplasia. The additional con-
trast provided by SPIO uptake at and around the pathogenic
tissue hypothetically allows for differentiation from hyper-
plastic marrow. A proposed scheme that parallels Kupffer
cell response to SPIO in the liver may be at work; at disease
sites SPIO are not taken up by cells in the bone-surrounding
epithelial layer.
Macrophage Imaging
The observation that SPIO are efficiently internalized by
macrophages and other phagocytic cells has recently led to
their evaluation as an MR contrast agent for the diagno-
sis of inflammatory and degenerative disorders associated
with high macrophage phagocytic activity. Applications
FIGURE 2. The use of intraveneously administered SPIO allows for the differentiation between normal and metastatic lymph
nodes. MR images of healthy lymph nodes before (A) and after (B) injection of SPIO shows a homogeneous decrease in the signal.
Conversly, MR images of a lymph node filled with a tumor shows a high signal intensity before (D) and after (E) administration of
SPIO. Panels (A), (B), (D), and (E) from Fig. 3 in Harsinghani, 2003.55
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have included identifying sites of transplant rejection71
and the identification of atherosclerotic plaques.75,130 Thus
far, evidence suggests that macrophage uptake of SPIO at
sites of atherosclerosis could indicate disease sites prior to
luminal narrowing, leading to earlier diagnosis and treat-
ment.124 It should be noted that the efficiency of SPIO up-
take by macrophage and MR contrast is highly dependent
on both circulation time and surface charge.90 Typically,
in vivo, smaller nanoparticles (15–30 nm hydrodynamic
diameter) with longer circulation times exhibit improved
contrast at sites of inflammation compared with larger
nanoparticles.53
The role of macrophages in pathologic tissue alterations
in the central nervous system (CNS) has also provided the
opportunity for the use of SPIO agents for the imaging of
strokes127 (Fig. 3), multiple sclerosis,33 brain tumors,2,37
and carotid atherosclerotic plaques.26 In ischemic stroke
lesions, the SPIO density and spatial distribution indicates
breakdown of the blood–brain barrier. Compartmental re-
lease of cytotoxic substances by activated macrophages po-
tentially leads to further CNS damage.12 In such cases,
SPIO-endowed in vivo visualization of macrophage activ-
ity presents an exciting opportunity to monitor the real-time
efficiency of therapeutic intervention. Clean delineation of
metastases in the brain was possible through SPIO pres-
ence, initially, at the tumor interstitium and, subsequently,
through uptake by surrounding tumor cells, approximately
24 h following injection.37 The definition provided at tumor
margins and of single tumor cells surrounding the tumor
(micrometastes) highlight the potential of SPIO for use in
preoperative planning.
ACTIVE TARGETING
In order to achieve active targeting of SPIO against spe-
cific biomolecules, it is necessary to first conjugate tar-
geting agents onto the SPIO surface directly or onto its
hydrophilic coating. An advantage of having a polymer
coating is that it can usually be modified to possess a variety
of reactive moieties (i.e., amines, sulfhydryls, carboxyls,
etc.), which subsequently allow for more control over
conjugation.
Perhaps the greatest hurdle for active targeting is local-
izing adequate levels of SPIO at a disease site to gener-
ate sufficient contrast for MR detection. With this goal in
mind, numerous approaches have been evaluated to effec-
tively enhance MR sensitivity by improving the site-specific
accumulation of SPIO. The most widely accepted tech-
nique involves intracellular trapping.72 In this approach,
receptor-mediated uptake of SPIO is exploited to accrue
elevated levels of the contrast agent within the desired
cells.
An alternative approach to improving MR contrast in-
volves a two-step amplification strategy.8 Specifically, a
biotinylated targeting antibody is first introduced intra-
venously and is allowed to localize to the specific disease
site. Streptavidin-labeled SPIO is then introduced to label
each antibody with multiple contrast agents. The avidin–
biotin binding system possesses extremely high binding
affinity and extension of this technique could be extended
to a wide range of targets, although, further development
of this targeting method is still required.
Active targeting is preferred to passive targeting since it
not only provides physiologic information but also offers
insight into specific molecular mechanisms. Such informa-
tion could allow for the early detection of disease as well
as more accurate staging. Numerous studies have already
demonstrated the ability of active targeting strategies to
identify early markers of cancer and cardiovascular disease,
the two leading causes of death.
Cancer Imaging
To date, numerous early markers of cancer have al-
ready been evaluated as targets for ligand-directed SPIO.
Achievement of satisfactory image contrast generally re-
quires that the targets selected are not only overexpressed
specifically on cancer cells, but also undergo receptor-
mediated endocytosis upon SPIO binding resulting in in-
tracellular accumulation. One such target is the transferrin
receptor, which is overexpressed on a variety of cancer cell
types—most notably breast cancer.142 Numerous studies
have shown that SPIO conjugated to transferrin can be used
to monitor the expression and regulation of the transferrin
receptor in vitro and in vivo.60,62,77,94,115
In parallel to the work with transferrin, SPIO conjugated
to folate experienced rapid and effcient uptake by tumor
cells overexpressing the folate receptor. In vivo MR imaging
revealed an average T2 intensity decrease of 38% from
pre-contrast to post-contrast images of the tumor.1,24,138
Another cancer marker recently targeted with SPIO is the
underglycosylated MUC-1 tumor antigen (uMUC-1). This
antigen is a common feature of numerous epithelial cell
adenocarcinomas including breast, pancreatic, colorectal,
lung, prostate, and gastric cancers. The antigen was targeted
with the peptide EPPT1, which has a known affinity for
uMUC-1.96
The number of biomarkers that have been targeted
with SPIO conjugates for detecting and imaging can-
cer in vivo continues to expand. To name a few; ma-
trix metalloproteinase-2, a membrane-bound endopepti-
dase found upregulated at gliomas, has been targeted.69
In this case, the contrast agent consisted of a SPIO–
chlorotoxin peptide conjugate.148 In another embodiment,
SPIO–herceptin was able to mark the HEr-2/neu (c-erb B-
2) tyrosine kinase receptor.9,44 This target has been found to
be overexpressed on breast cancer cells in 25% of women
with metastatic breast cancer. Additionally, a monoclonal
antibody bound to SPIO was able to bind an unknown ligand
expressed in colorectal cancers.143
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FIGURE 3. Non-enhanced T1-weighted image brainstem infarct (arrow) 5 days after stroke (A). A gadolinium contrast agent shows
no breach of blood–brain barier (B). Images at 24 h (C) and 48 h (D) following SPIO infusion show amplified signal at infarcted
parenchyma (from A. Saleh, 2004,109).
An alternative strategy for identifying tumors involves
targeting receptors specifically expressed on normal tis-
sues but not tumors. Such a design has been pursued with
the CholocystokininA (CCKA) receptor of pancreas acinar
cells. CCK is a hormone produced principally by the small
intestine in response to the presence of fats that binds to the
receptor CCKA. Studies show that upon administration of
SPIO–CCK to rats, a significant reduction of T2 relaxation
in normal pancreatic tissues but not in tumors was evident,
illustrating the feasibility of SPIO-mediated detection of
tumors in the pancreas.120
The liver is a common site of metastases from a variety
of organs including the breasts, lungs, rectum, and colon.
Accordingly, much effort has been expended in the research
for liver-specific MR contrast agents to characterize liver
tumors. It is known that asialoglycoprotein (ASG) recep-
tors are present on normal hepatocytes but are missing in
primary malignant or metastatic tumors.119 To detect liver
cancer in rats, SPIO were conjugated to arabinogalactan
(AG), a polysacharride that is a ligand of the ASG receptor.
MR imaging indicated that the use of AG–SPIO to target
normal hepatocytes allows for enhanced tumor–liver con-
trast.120
Imaging Apoptosis
An emerging exploitation of SPIO is the active targeting
of cells undergoing apoptosis. Apoptosis plays a role in the
pathology of cancer, neurodegeneration, acute myocardial
infarction, and chronic inflammation. SPIO targeting
apoptotic cells and cues could also allow for the real-time
monitoring of drug efficacy. Recently, in vivo apoptotic
cell detection via MR has been accomplished through the
use of the first C2 domain of synaptotagmin I as a targeting
moiety.163 When conjugated to SPIO, significant increases
in image contrast were identified in those regions of tumors
containing large numbers of apoptotic cells. An alternative
method currently being developed for imaging apoptosis
involves targeting of the phospholipid phosphatidylserine
(PS) with Annexin V.36 Using Annexin V-conjugated
nanoparticles, apoptotic cells could be detected at nanopar-
ticle concentrations as low as 0.1 µg Fe/ml in vitro.128,129
Cardiovascular Imaging
In addition to cancer and apoptosis, molecular imag-
ing has also taken great strides in improving the con-
trast and early detection of various cardiovascular diseases
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FIGURE 4. MR image of atherosclerotic lesion targeted with
SPIO. (A) Following injection of VCAM-1 targeted SPIO into
apolipoprotein-deficient mice, clear decreases in signal inten-
sity could be detected in atherosclerotic lesions. Panel (A) from
Fig. 6 in Kelly, 2005.63
including atherosclerosis, thrombosis, and myocardial in-
farcts. Detection of early atherosclerotic signatures has
recently been performed with anti-VCAM-1 (vascular ad-
hesion molecule-1)-targeted SPIO,145 as well as SPIO la-
beled with VCAM-1-specific peptides.72 In the latter case,
phage display was used to identify a VCAM-1-specific cell
internalizing peptide. Internalization of the SPIO–peptide
conjugates reportedly resulted in a 12-fold higher target-to-
background ratio compared with anti-VCAM-1–SPIO con-
jugates. Through the increased uptake and subsequent com-
partmental accumulation of SPIO, sites of atherosclerosis
were identified in apolipoprotein-deficient mice through the
resultant decrease of signal intensity (Fig. 4). Since VCAM-
1 has been identified as an early marker for inflammation
of the endothelium it is envisioned that these nanoparticles
could potentially lead to earlier diagnosis and treatment.
In addition to VCAM-1, E-selectin has also been val-
idated as a potential target for SPIO. E-selectin is a
proinflammatory marker of endothelial cells that has been
implicated in atherosclerosis, tumor vascular endothelial
proliferation, and angiogenesis.15,23,76 Using SPIO–anti-
human E-selectin F(ab′)2 conjugates, E-selectin was de-
tected by MR imaging in human endothelial cell cultures,
exhibiting a significant contrast enhancement over control
cells.70
Imaging of thrombi has recently been accomplished
through the specific detection of both αIIb-β3, which is
expressed by activated platelets, and activated coagulation
factor XIII (FXIIIa), a tissue transglutaminase that cross-
links fibrin and plasmin inhibitors to form stable thrombi.7
Activated platelets were targeted with SPIO–RGD peptide
conjugates in both ex vivo and in vivo thrombus models.65
It is well established that RGD, a cyclic arginine-glycine-
aspartic acid peptide, specifically targets the αIIb-β3 in-
tegrin.125 SPIO–RGD resulted in better thrombus visual-
ization than non-targeted SPIO ex vivo. Furthermore, with
MR contrast enhancement, clot visualization in vivo was
achieved with an in-plane resolution of less than 0.2 mm ×
0.2 mm. FXIIIa was detected in vivo using an alpha2AP
peptide–SPIO conjugate. Previous reports have demon-
strated that alpha2AP peptide is effectively cross-linked by
FXIIIa. Results indicated that SPIO–alpha2AP was cova-
lently linked to human plasma thrombi, and MR imaging
revealed a marked thrombus contrast enhancement over
control agents.64
For imaging of myocardial infarcts, antimyosin Fab
(R11D10), which are immunospecific to necrotizing my-
ocytes, were conjugated to SPIO. Images showed signifi-
cant signal decrease of the infarct relative to the surrounding
myocardium.158
CELL TRACKING
A promising new direction for SPIO is their use in
tracking the biodistribution of cells in vivo. These studies
typically involve implanting SPIO-loaded cells into living
subjects and tracking their movement and localization at
specific tissues.43 Various strategies have been employed to
efficiently load cultured cells with enough SPIO to ensure
sufficient contrast for in vivo imaging.6 Of particular in-
terest is the conjugation of membrane translocating signals
such as HIV-Tat and polyArginine peptides to SPIO, which
greatly enhance SPIO uptake into many cell types.68,80 The
potential of in vivo cell tracking has been demonstrated
in several systems including SPIO loaded T cells.31 Ob-
jects as diminutive as single cells were able to be mon-
itored since the T2 relaxation effect of the sequestered
magnetic nanoparticles is exerted over a region larger than
that of the cell itself. SPIO labeled T cells showed a 20%
reduction of signal in the spleen of mice at 3 h post-
injection.30 This correlates with the known pattern of T-cell
distribution following injection in mice. The tracking of
immune responsive cells, whose activation has been shown
to not be impaired in the presence of SPIO,30 could allow
for specific diagnosis and monitoring of treatment.
More recently SPIO has been used to track stem cells
upon seeding to a target organ. The distribution of rat mes-
enchymal stem cells following intravascular injection16 has
been recorded. Non-invasive imaging through T2 drop of
the contrast agent was used to track the cells to the kidney
and livers of injected rats.
A trimodal (magnetic, fluorescent, isotope) HIV-Tat
peptide-labeled CLIO probe was developed and tested80 in
human lymphocytes and hematopoietic cells and in mouse
splenocytes and neuronal progenitor cells. The cells were
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FIGURE 5. Detection of nucleic acids with magnetic relaxation switches (MRS). (E) A color-coded T2-weighted MR image of a
384-well plate with constant amounts of P1 and P2 probes, with varying amounts of matching and mismatched Target. (F) MRI
values show the linear drop in T2 correlated to concentration. The sensitivity of the ON MRS nanosensors is robust and sensitive
enough to be able to detect extremely low concentrations of probe hybridization. Panels (E) and (F) from Fig. 2 in Perez, 2002.105
traceable in vivo following implantation in immunodefi-
cient mice, offering detection at the single-cell level.
Internalizing cell surface receptor-mediated endocytosis
of SPIO is another avenue through which cell migration
can be observed in vivo.27 Bulte and coworkers utilized
anti-transferrin receptor antibodies conjugated to nanopar-
ticles in order to observe oligodendrocyte migration post-
neurotransplantation.19 The SPIO did not interfere with the
cells’ ability to myelinate in vivo, and histological evalua-
tion of the cells with nanoparticles revealed cell migration
up to 10 mm in 14 days.
MAGNETIC RELAXATION SWITCHING
It has previously been observed that SPIO assemblies
undergo a unique magnetic phenomenon, termed magnetic
relaxation switching (MRS).67,105,107,144,164 During this co-
operative process, the superparamagnetic iron oxide core of
individual nanoparticles become more efficient at dephas-
ing the spins of surrounding water protons, i.e., at enhancing
spin–spin relaxation times (T2). Recently, this mechanism
has been exploited as a tool for detecting biomolecules
in homogeneous assays and has demonstrated detection
limits as low as 500 attomoles.105 Applications have in-
cluded the detection of oligonucleotides (ON), proteins,
enzymes, and enantiomers with very high sensitivity. A
major advantage of MRS over many detection schemes is
that magnetic changes are detectable in turbid media and
whole-cell lysates without the need for protein purification.
The tremendous sensitivity of MRS combined with the abil-
ity to detect SPIO in deep tissue make MRS a promising
approach for in vivo applications; although, strategies must
still be developed to limit false-positives due to the non-
specific aggregation of nanoparticles within endosomes.
Oligonucleotide Detection
The capability of MRS was first demonstrated with the
detection of nucleic acids in solution.67,105 Specifically,
two unique SPIO populations were synthesized, where
the SPIO-ON constructs were designed to recognize ad-
jacent sites on a nucleic acid target. SPIO self-assembly
induced by hybridization to target DNA generated a de-
tectable change in the T2 relaxation time. Conversely, lit-
tle signal change was detected when SPIO-ON conjugates
were introduced to a non-complementary nucleic acid target
(Fig. 5). The lower detection limit for this assay was shown
to be less than 500 attomoles. Further, the binding occurred
within minutes and was reversible. An interesting appli-
cation of this technique, in a high-throughput screening
scheme, is the measurement of telomerase activity, a metric
of genetic instability and associated with the formation of
malignancies.49 As little as 10–100 attomoles of target were
detected using a benchtop relaxometer. Atomic force mi-
croscopy allowed for single molecule detection confirming
the SPIO-ON conjugates alignment along target telomeric
repeats.
Protein and Enzyme Detection
MRS probes have also been exploited as biosensors
capable of detecting specific proteins and even viruses
via antibody-mediated interactions.108 For example, SPIO
labeled with surface-specific antibodies raised against
adenovirus-5 and herpes simplex virus-1 were used to detect
as few as five viral particles per 10 µl via the MRS-based
mechanism. A similar detection scheme was also used to
detect proteins (e.g., GFP) in cell lysate.105
Complementary to MRS assays dependent on the self-
assembly of SPIO, assays relying the dispersion of SPIO
have also been devised to detect endonuclease, and sub-
sequently, methylase and protease activity.105,106 Briefly,
for endonuclease activity, two sets of SPIO were designed
such that attached oligonucleotide sequences hybridized to
form a restriction endonuclease recognition site. The T2
relaxation time decreased significantly when the two pop-
ulations were combined. Subsequent addition of restriction
endonucleases resulted in an increase in the T2 relaxation
time as the restriction sites were cleaved. This method has
also been modified for methylases and proteases by simply
switching endonuclease substrates to methylase and pro-
tease substrates, respectively.
For MRS assays that are intended for in vivo appli-
cations, detection strategies that rely on association of
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SPIO rather than dissociation are typically preferred to cir-
cumvent the problem of glomerular filtration of clustered
nanoparticles. Accordingly, MRS sensors for myelperoxi-
dase (MPO), an enzyme associated with atherosclerosis and
inflammation,162 were designed as serotonin-labeled SPIO
which become cross-linked in the presence of MPO.107 Al-
though not validated in vivo, these probes certainly take the
first steps toward extending MRS-based probes into living
subjects.
Enantiomer Detection
Most recently, MRS nanoparticles have been developed
to serve as a highly sensitive sensor for enantiomeric im-
purities.144 Evidence that considerable differences may be
present in the pharmacological activity of certain enan-
tiomers has led to an urgent demand for a system that can
detect enantiomeric impurities with high sensitivity, quick
execution, and high-throughput capability. To help meet
this demand, an MRS-based model system was established
where SPIO were first labeled with the enantiomer D-Phe,
(SPIO-D-Phe) considered to be the impurity in this case.
Antibodies raised against D-Phe were then added to the so-
lution of SPIO-D-Phe resulting in the formation of clusters
and a corresponding decrease in the T2 relaxation time.
Upon the addition of racemic mixtures of L- and D-Phe, the
presence of D-Phe impurities led to the dispersion of the
nanoparticles by competing with the SPIO-D-Phe for anti-
D-Phe binding sites. This resulted in a detectable increase in
the T2 relaxation time. The MRS enantiomeric immunoas-
say proved capable of detecting enantiomeric impurities at
levels far below the requirements of the federal regulatory
agencies and also could be adapted to a high-throughput
format for pharmaceutical applications.
CONCLUDING REMARKS
The use of MR imaging has become a well-established
means for injury and disease diagnosis on the anatomic
scale. The search for contrast agents to improve contrast
via MR has spurred the development and use of SPIO as a
means for imaging not only at the anatomical scale but also
the cellular and even molecular level. The intensification of
these developments, in the fields of materials science, nan-
otechnology, and bioconjugation chemistry, has pushed the
use of these agents to the boundaries of molecular imaging
and beyond. Applications as diverse as cell tracking, gene
detection and quantification, molecular interaction, and en-
zymatic reactions are being observed through the use of
SPIO probes.
A motivating advantage for advancing MR as a plat-
form for molecular imaging is that anatomic and molecular
information can be gathered simultaneously. Contrarily, a
significant drawback of an MR-based approach to molec-
ular imaging is its low sensitivity, particularly compared
with nuclear imaging, which has been used to detect probes
down to the picomolar level.110 The inherently low signal-
to-noise ratio in MR can be amended through longer scan
times, which can become prohibitively long, and the use of
stronger magnetic fields. The vast majority of clinical MR
units are however at 1.5 T. It should be noted that imaging of
individual cells has been accomplished on a clinical scanner
with some modifications.42
Another limitation of MR-based molecular imaging is
the current inability to image more than one biomarker
at a time as is commonly performed with optical imag-
ing in combination with contrast agents such as quantum
dots. Quantum dots are nanoparticles composed of semi-
conductor material that are currently in favor thanks to their
minimal bleaching (as opposed to fluorophores), a variety
of emission wavelengths as controlled by their diameter,
and the ability to be conjugated to molecular targeting moi-
eties similar to SPIO (for an introduction, see Gao45). Each
imaging modality (e.g., MR, optical, nuclear, etc.) clearly
exhibits unique advantages and disadvantages when applied
to molecular imaging applications and they will undoubt-
edly continue to compliment each other in the future, partic-
ularly with the introduction of new multi-modality imaging
platforms.
Effective and innovative imaging approaches are in great
demand as new proteins and genes, particularly within the
field of oncology, are being discovered at an ever-increasing
pace. This provides a constantly multiplying library of
molecules and pathways to be studied for prevention, di-
agnosis, and treatment of diseases. The full potential of
new discoveries is however limited by the void between the
advances in bioscience and the means to accurately, effec-
tively and—critically—non-invasively image the molecular
interactions in biological systems. Many challenges clearly
remain in the pursuit of ideal SPIO probes for molecular
imaging; increased target affinity, less complex conjuga-
tion schemes, reduction of cost, a means for MRS to avoid
sequestration in lysosomes and more effective activatable
probes. With persistent advances, this system continues to
demonstrate its potential as a means to probe deeper into
our biological universe.
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